A number of research firms have changed their ratings and price targets for Centene (NYSE: CNC):
- 6/23/2026 – Centene is now covered by Royal Bank Of Canada. They set a “sector perform” rating and a $70.00 price target on the stock.
- 6/16/2026 – Centene had its “overweight” rating reaffirmed by Barclays PLC.
- 6/11/2026 – Centene had its “overweight” rating reaffirmed by Cantor Fitzgerald.
- 6/8/2026 – Centene was given a new $63.00 price target by Mizuho. They now have a “neutral” rating on the stock.
- 6/8/2026 – Centene had its price target raised by JPMorgan Chase & Co. from $52.00 to $60.00. They now have a “neutral” rating on the stock.
- 6/4/2026 – Centene had its price target raised by Bank of America Corporation from $72.00 to $74.00. They now have a “buy” rating on the stock.
- 6/4/2026 – Centene had its price target raised by Morgan Stanley from $50.00 to $57.00. They now have an “equal weight” rating on the stock.
- 6/1/2026 – Centene had its price target raised by Truist Financial Corporation from $58.00 to $71.00. They now have a “buy” rating on the stock.
- 5/27/2026 – Centene had its price target raised by Oppenheimer Holdings, Inc. from $58.00 to $67.00. They now have an “outperform” rating on the stock.
- 5/26/2026 – Centene had its price target raised by Barclays PLC from $63.00 to $75.00. They now have an “overweight” rating on the stock.
- 5/22/2026 – Centene had its “neutral” rating reaffirmed by UBS Group AG. They now have a $61.00 price target on the stock, up from $55.00.
- 5/21/2026 – Centene had its price target raised by Bank of America Corporation from $60.00 to $72.00. They now have a “buy” rating on the stock.
- 5/20/2026 – Centene was given a new $58.00 price target by Mizuho. They now have a “neutral” rating on the stock.
- 5/20/2026 – Centene was upgraded by Deutsche Bank Aktiengesellschaft from “hold” to “buy”. They now have a $80.00 price target on the stock, up from $53.00.
- 5/6/2026 – Centene was upgraded by Zacks Research from “hold” to “strong-buy”.
- 5/5/2026 – Centene had its price target raised by JPMorgan Chase & Co. from $41.00 to $52.00. They now have a “neutral” rating on the stock.
- 5/5/2026 – Centene had its price target raised by Sanford C. Bernstein from $48.00 to $68.00. They now have an “outperform” rating on the stock.
- 5/4/2026 – Centene had its “hold” rating reaffirmed by TD Cowen. They now have a $47.00 price target on the stock, up from $38.00.
- 5/2/2026 – Centene was upgraded by Wall Street Zen from “hold” to “buy”.
- 5/1/2026 – Centene had its price target raised by Wells Fargo & Company from $44.00 to $56.00. They now have an “equal weight” rating on the stock.
Centene Corporation (NYSE: CNC) is a diversified, multi-national healthcare enterprise that specializes in providing services to government-sponsored and national health programs. The company primarily acts as a managed care organization, delivering healthcare coverage and administering benefits for Medicaid, the Children’s Health Insurance Program (CHIP), Medicare Advantage, and individual marketplace plans. Centene also contracts with federal and state agencies to manage specialty care programs and community-based services for vulnerable populations.
Centene’s offerings extend beyond traditional insurance to include a range of specialty and support services.
Featured Stories
- Five stocks we like better than Centene
- 5 Tech Stocks to Buy on the July Pullback
- Is OpenAI’s IPO Delay a Warning for AI Investors?
- onsemi: What the Market Gets Wrong, You Can Get Right
- Is McCormick a Steal Ahead of Game-Changing Unilever Deal?
Receive News & Ratings for Centene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
